|
|
|
|
|
|
Sponsored by: |
Orexigen Therapeutics, Inc |
Information provided by: | Orexigen Therapeutics, Inc |
ClinicalTrials.gov Identifier: | NCT00709371 |
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
Condition | Intervention | Phase |
Obesity |
Drug: Zonisamide SR placebo plus bupropion SR placebo Drug: Zonisamide SR placebo plus bupropion SR 360 mg/day Drug: Zonisamide SR 120 mg/day plus bupropion SR placebo Drug: Zonisamide SR 360 mg/day plus bupropion SR placebo Drug: Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day Drug: Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day |
Phase II |
MedlinePlus related topics: | Obesity |
Drug Information available for: | Bupropion hydrochloride Bupropion Zonisamide |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment |
Official Title: | A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Uncomplicated Obesity |
Estimated Enrollment: | 600 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Placebo Comparator
Zonisamide SR placebo plus bupropion SR placebo
|
Drug: Zonisamide SR placebo plus bupropion SR placebo
2 placebo tablets twice daily for 16 weeks (maintenance period)
|
2: Active Comparator
Zonisamide SR placebo plus bupropion SR 360 mg/day
|
Drug: Zonisamide SR placebo plus bupropion SR 360 mg/day
2 placebo and bupropion SR 90 mg tablets, twice daily for 16 weeks (maintenance period)
|
3: Active Comparator
Zonisamide SR 120 mg/day plus bupropion SR placebo
|
Drug: Zonisamide SR 120 mg/day plus bupropion SR placebo
2 zonisamide SR 30 mg and placebo tablets, twice daily for 16 weeks (maintenance period)
|
4: Active Comparator
Zonisamide SR 360 mg/day plus bupropion SR placebo
|
Drug: Zonisamide SR 360 mg/day plus bupropion SR placebo
2 zonisamide SR 90 mg and placebo tablets, twice daily for 16 weeks (maintenance period)
|
5: Experimental
Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day
|
Drug: Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day
2 zonisamide SR 30 mg and bupropion SR 90 mg tablets, twice daily for 16 weeks (maintenance period)
|
6: Experimental
Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day
|
Drug: Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day
2 zonisamide SR 90 mg and bupropion SR 90 mg tablets, twice daily for 16 weeks (maintenance period)
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 20 Study Locations |
Orexigen Therapeutics, Inc |
Principal Investigator: | Matthew Acampora, MD | Internal Medicine Associates of Charlotte |
Principal Investigator: | Caroline Apovian, MD | Nutrition and Weight Management Center |
Principal Investigator: | James Bergthold, MD | Summit Research Network (Oregon), Inc. |
Principal Investigator: | Joseph Cleaver, MD | The Cooper Institute |
Principal Investigator: | Adnan Dahdul, MD | FutureCare Studies |
Principal Investigator: | Ken Fujioka, MD | Nutrition and Metabolic Research |
Principal Investigator: | Jeffrey Geohas, MD | Radiant Research, Chicago |
Principal Investigator: | Mark Graves, MD | Welborn Clinic |
Principal Investigator: | Alok Gupta, MD | Pennington Biomedical Research Center |
Principal Investigator: | Wayne Harper, MD | Wake Research Associates, LLC |
Principal Investigator: | Jonathan Henry, MD | Summit Research Network (Michigan), Inc. |
Principal Investigator: | Diane Krieger, MD | Miami Research Associates |
Principal Investigator: | Michael Levy, MD | Behavioral Medical Research |
Principal Investigator: | Raymond Plodkowski, MD | Center for Nutrition and Metabolic Disorders, University of Nevada School of Medicine |
Principal Investigator: | Domenica Rubino, MD | Washington Center for Weight Management and Research |
Principal Investigator: | Stan Self, MD | SelfCenter, PC |
Principal Investigator: | Diane Smith, MD | CSRA Partners in Health, Inc. |
Principal Investigator: | Timothy Smith, MD | Mercy Health Research |
Principal Investigator: | Claire Waltman, MD | Summit Research Network (Seattle), LLC |
Principal Investigator: | Holly Wyatt, MD | Center for Human Nutrition/UCD |
Responsible Party: | Orexigen Therapeutics, Inc. ( Dr. Ronald Landbloom ) |
Study ID Numbers: | ZB-202 |
First Received: | June 29, 2008 |
Last Updated: | October 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00709371 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
|
|
|
|
|